Evidence map›Paper›PMID 34771016›Full record

ArticleMolecules (Basel, Switzerland)2021

Molecular Evidence of the Inhibitory Potential of Melatonin against NaAsO

Maryam Baeeri, Tina Didari, Madiha Khalid, Solmaz Mohammadi-Nejad, Seyed Mojtaba Daghighi, Ramtin Farhadi, Mahban Rahimifard, Zahra Bayrami, Hamed Haghi-Aminjan, Roham Foroumadi and 2 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maryam BaeeriToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Tina DidariToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.ORCID 0000-0002-6116-8451
Madiha KhalidToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.ORCID 0000-0002-4538-1922
Solmaz Mohammadi-NejadToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Seyed Mojtaba DaghighiToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Ramtin FarhadiToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Mahban RahimifardToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Zahra BayramiToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Hamed Haghi-AminjanPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil 5618953141, Iran.ORCID 0000-0002-7863-6821
Roham ForoumadiDepartment of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran 13145784, Iran.
Mahdi GholamiToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Mohammad AbdollahiToxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417613151, Iran.ORCID 0000-0003-0123-1209

Funding

National Institute for Medical Research Development 972793
6 · The paper itself

Abstract

Arsenic (As) poisoning is widespread due to exposure to pollution. The toxic level of (As) causes oxidative stress-induced aging and tissue damage. Since melatonin (MLT) has anti-oxidant and anti-aging properties, we aimed to evaluate the protective effect of MLT against the toxicity of sodium arsenite (NaAsO

Indexed as

AgingAnimalsArsenitesMaleMelatoninMiceSodium CompoundsArsenitesMelatoninsodium arseniteSodium CompoundsagingKlothoMelatoninsodium arseniteTERTTRADD

Identifiers

PMID34771016
PMCPMC8587717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.